Prevention of urethral fibrosis induced by transforming growth factor beta 1 using selective Wnt/β‐catenin signaling inhibitors in a rat model
- 5 April 2022
- journal article
- research article
- Published by Wiley in International Journal of Urology
- Vol. 29 (7) , 764-771
Abstract
Objectives To determine the anti-fibrotic effects of Wnt/beta-catenin signaling inhibitors on urethral stricture. Methods Human fibroblasts were exposed to transforming growth factor beta 1 combined with various concentrations of Wnt/beta-catenin inhibitors (ICG-001, IWR-1, and PRI-724), and cell proliferation and migration were evaluated. Urethral fibrosis was induced in male Sprague-Dawley rats by urethral injection of transforming growth factor beta 1 and co-treatement with inhibitors. Urethral tissues were harvested 2 weeks after the injection. The messenger ribonucleic acid and protein expression was examined for fibrosis markers Axin-1, collagen type 1, alpha smooth muscle actin, and beta-catenin. Histological analysis of fibrosis and collagen deposition was also performed. Results Cell migration was ameliorated by ICG-001 and PRI-724. Protein and messenger ribonucleic acid expression of collagen type 1 and alpha smooth muscle actin in transforming growth factor beta 1-treated fibroblasts decreased in a concentration-dependent manner with the ICG-001 and PRI-724 treatments (P < 0.05). However, there were no significant changes with the IWR-1 treatment. Collagen type I and alpha smooth muscle actin messenger ribonucleic acid and protein expression were both significantly increased in the urethral tissues of rats with transforming growth factor beta 1-induced urethral fibrosis. Rats co-treated with ICG-001 or PRI-724 showed relatively mild fibrosis and significantly reduced collagen type I and alpha smooth muscle actin messenger ribonucleic acid and protein expression (P < 0.05). Conclusions ICG-001 and PRI-724 significantly ameliorated urethral fibrosis induced by transforming growth factor beta 1 in rats. These results suggest that ICG-001 and PRI-724 can be developed as therapeutics for treating urethral stricture.Keywords
Funding Information
- Ministry of Education (NRF‐2018R1D1A1A02085556)
This publication has 29 references indexed in Scilit:
- Prevention of Stricture Recurrence Following Urethral Endoscopic Management: What Do We Have?Journal of Endourology, 2013
- Involvement of the Wnt/β-Catenin Signaling Pathway in the Cellular and Molecular Mechanisms of Fibrosis in EndometriosisPLOS ONE, 2013
- The Small Molecule Wnt Signaling Modulator ICG-001 Improves Contractile Function in Chronically Infarcted Rat MyocardiumPLOS ONE, 2013
- Structural Basis of Selective Inhibition of Human TankyrasesJournal of Medicinal Chemistry, 2012
- Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosisNature Communications, 2012
- Inhibition of Wnt/β-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosisProceedings of the National Academy of Sciences, 2010
- Wnt–β-catenin signalingCurrent Biology, 2008
- SnapShot: Wnt/β-Catenin SignalingCell, 2007
- A morphometric analysis of bulbar urethral stricturesBJU International, 2007
- A small molecule inhibitor of β-catenin/cyclic AMP response element-binding protein transcriptionProceedings of the National Academy of Sciences, 2004